Allogene Therapeutics Inc (ALLO)vsAlnylam Pharmaceuticals Inc (ALNY)
ALLO
Allogene Therapeutics Inc
$2.44
+17.87%
HEALTHCARE · Cap: $465.19M
ALNY
Alnylam Pharmaceuticals Inc
$312.17
+0.34%
HEALTHCARE · Cap: $41.40B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.4% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALLO
Avoid27
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALLO.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$312.17
$296.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 52.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALLO
The strongest argument for ALLO centers on Price/Book.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ALLO
The primary concerns for ALLO are EPS Growth, Market Cap, Profit Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 133.4x leaves little room for execution misses.
Key Dynamics to Monitor
ALLO profiles as a value stock while ALNY is a hypergrowth play — different risk/reward profiles.
ALLO carries more volatility with a beta of 0.50 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 27/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Allogene Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?